Lupus Erythematosus, Systemic Clinical Trial
Official title:
The Effect of Green Tea Extract on Some Inflammatory Biomarkers(IL 6, IL1β,TNF α,CRP), Serum Total Antioxidant Capacity(TAC), MDA and Disease Activity in Patients With Systemic Lupus Erythematous
This randomized double blind clinical trial performed on 68 patients (32 in intervention and
36 in control group) diagnosed with SLE. The patients in intervention group were given daily
dose of 1000mg of aqueous green tea extract (of 6 gram of dried green tea leaf) in form of
two capsules ( 500 mg). Also in control group, the patients were given daily dose of 1000mg
of cellulose in form of two capsules ( 500 mg) Variables include SLE disease activity, some
biomarkers of inflammation and oxidative stress and anthropometric indicators at baseline
and end of the study.
The investigators used SLEDAI (systemic lupus erythematous disease activity index )
questionnaire for evaluating the clinical signs of the disease. The questionnaires filled
out at baseline and after 3 month.
noting ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Recruiting |
NCT05967520 -
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT02922114 -
Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients
|
N/A | |
| Withdrawn |
NCT01702038 -
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
|
Phase 2 | |
| Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
| Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
| Completed |
NCT00065806 -
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
|
Phase 3 | |
| Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A | |
| Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
| Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
| Recruiting |
NCT05899907 -
Efficacy and Safety of Telitacicept in Early SLE
|
Phase 4 | |
| Completed |
NCT04956484 -
Belimumab In Early Systemic Lupus Erythematosus
|
Phase 4 | |
| Completed |
NCT05326841 -
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
|
Phase 3 | |
| Completed |
NCT02655640 -
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
|
N/A | |
| Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
| Terminated |
NCT00089804 -
Study of LJP 394 in Lupus Patients With History of Renal Disease
|
Phase 3 | |
| Completed |
NCT00071487 -
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
| Completed |
NCT02349061 -
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT05636670 -
Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
|
||
| Recruiting |
NCT03747159 -
Synergetic B-cell Immunomodulation in SLE - 2nd Study.
|
Phase 3 |